A fact is that I think there is a Disallowed coming up here. Of course it could be classed as ramping, but if the EU trial is approved I think it is a very good possibility from this cash level. You just keep looking at the past while we have a healthy company here with a Phase3 registration trial planned, with the first drug in a wide platform of neurodegeneration drugs, at just above cash value. I am just a holder and very happy with my investment if/when they get the EU trial underway. If they don't get approval for a trial, we are already close to cash. If they do it unlocks the whole 2000+ drug library and look out.
Ann: Prana provides regulatory update for PBT2-PBT.AX, page-67
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $4.579K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 749591 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 133062022 | 26 |
View Market Depth
| Last trade - 14.03pm 13/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |